Royalty Pharma (RPRX) Non-Current Assets (2019 - 2026)
Royalty Pharma (RPRX) posted Non-Current Assets of $18.4 billion for Q1 2026, up 1.64% sequentially from $18.1 billion in Q4 2025, and up 16.65% YoY from $15.8 billion in Q1 2025.
Royalty Pharma (RPRX) Non-Current Assets (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Non-Current Assets for 8 years, with the latest figure at $18.4 billion in Q1 2026.
- Quarterly Non-Current Assets rose 16.65% year-over-year to $18.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $70.8 billion (up 11.45% YoY) and the FY2025 annual result came in at $18.1 billion, up 10.18% from the prior year.
- Non-Current Assets rose to $18.4 billion in Q1 2026 per RPRX's latest filing, from $18.1 billion in the prior quarter.
- Over five years, Non-Current Assets peaked at $18.4 billion in Q1 2026 and troughed at $14.1 billion in Q3 2023.
- A 5-year average of $15.6 billion and a median of $15.1 billion in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2026: Non-Current Assets declined 7.85% in 2023, then gained 16.65% in 2026.
- Over 5 years, Non-Current Assets stood at $14.3 billion in 2022, then grew by 5.96% to $15.1 billion in 2023, then grew by 8.69% to $16.4 billion in 2024, then climbed by 10.18% to $18.1 billion in 2025, then gained by 1.64% to $18.4 billion in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $18.4 billion, $18.1 billion, and $17.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 564.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.06 Bn |
| Mar 31, 2026 | 18.39 Bn |
| Dec 31, 2025 | 18.09 Bn |
| Sep 30, 2025 | 17.50 Bn |
| Jun 30, 2025 | 16.80 Bn |
| Mar 31, 2025 | 15.77 Bn |
| Dec 31, 2024 | 16.42 Bn |
| Sep 30, 2024 | 16.25 Bn |
| Jun 30, 2024 | 15.08 Bn |
| Mar 31, 2024 | 14.57 Bn |
| Dec 31, 2023 | 15.11 Bn |
| Sep 30, 2023 | 14.13 Bn |
| Jun 30, 2023 | 14.17 Bn |
| Mar 31, 2023 | 14.44 Bn |
| Dec 31, 2022 | 14.26 Bn |
| Sep 30, 2022 | 15.33 Bn |
| Jun 30, 2022 | 14.24 Bn |
| Mar 31, 2022 | 14.40 Bn |
| Dec 31, 2021 | 14.64 Bn |
| Sep 30, 2021 | 14.96 Bn |